Related Experiment Videos
Genetic susceptibility to iatrogenic malignancy.
James M Allan1, Charles S Rabkin
1Department of Biology, Epidemiology and Genetics Unit, University of York, York, UK. jim.allan@egu.york.ac.uk
Pharmacogenomics
|September 7, 2005
Summary
Iatrogenic malignancies, cancers caused by medical treatment, are increasing in cancer survivors. Host genetic factors influencing treatment response are key to identifying high-risk individuals.
Area of Science:
- Oncology
- Genetics
- Cancer Survivorship
Background:
- Iatrogenic malignancies are a serious long-term consequence of cancer therapy.
- Improved cancer survival rates have led to a rise in secondary cancers.
- Identifying susceptible individuals is crucial for risk management.
Purpose of the Study:
- To explore host genetic factors influencing the development of iatrogenic malignancies.
- To understand how genetic variations impact patient susceptibility to secondary cancers after treatment.
Main Methods:
- Review of genetic pathways involved in drug metabolism and DNA repair.
- Identification of polymorphic loci associated with treatment response.
- Analysis of genes such as glutathione S-transferases and DNA repair enzymes.
Main Results:
- Genetic variations in detoxification enzymes (e.g., glutathione S-transferases, NAD(P)H:quinone oxidoreductase) affect treatment dose.
- Polymorphisms in DNA repair pathways (e.g., nucleotide excision repair) influence cellular outcomes.
- Host genetics play a significant role in iatrogenic malignancy risk.
Conclusions:
- Understanding host genetic susceptibility is vital for personalized cancer treatment strategies.
- Targeting specific genetic pathways may help mitigate the risk of secondary malignancies.
- Further research into genetic modifiers can improve long-term cancer survivorship.